Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Feb;21(2):195-198.
doi: 10.1093/annonc/mdp595.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

Affiliations
Editorial

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

R Colomer et al. Ann Oncol. 2010 Feb.
No abstract available

PubMed Disclaimer

Comment in

  • Treatment of cancer with drugs: a controversy.
    Guedea F, Macià M, Sanchez Calzado JA, Ramos A, Lopez Torrecilla JL, Herruzo I, Contreras J, Romero J, Willisch P; (Board of SEOR) on behalf of the Spanish Society for Radiation Oncology. Guedea F, et al. Ann Oncol. 2011 Mar;22(3):747-748. doi: 10.1093/annonc/mdq760. Ann Oncol. 2011. PMID: 21343385 No abstract available.
  • Treatment of thyroid cancer with the new oral agents.
    Galofré JC, Gómez-Sáez JM, Escola CA, Anda E, Calleja A, Donnay S, Lucas-Martin A, Menéndez-Torre E, Pereg V, Pérez-Corral B, Santamaría J, Riesco-Eizaguirre G, Zafon C; Thyroid Cancer Committee from the Spanish Society of Endocrinology and Nutrition (SEEN). Galofré JC, et al. Ann Oncol. 2011 Oct;22(10):2343. doi: 10.1093/annonc/mdr409. Epub 2011 Aug 22. Ann Oncol. 2011. PMID: 21859897 No abstract available.
  • Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology.
    Villavicencio H, Hernández C, Gómez A, Cózar JM, Rodríguez-Antolín A, Prieto L, de Cabo M, Malet JM, Extramiana J, Mata J, Arrabal M, Server G, Solsona E, Del Valle JI, Miguélez E, Gutiérrez E, Elizalde A, Mateos J, Artiles JL, Jiménez-Cidre M, Nalda LM, Cruz N, Ozonas M, Caffaratti J, Esteban M, Unda M, Reina C, Alvarez-Ossorio JL, Lledó E, Angulo JC. Villavicencio H, et al. Actas Urol Esp. 2013 Jun;37(6):321-3. doi: 10.1016/j.acuro.2013.04.001. Epub 2013 May 23. Actas Urol Esp. 2013. PMID: 23706692 English, Spanish. No abstract available.

References

    1. Bajetta E, Gevorgyan A, Mellstedt H. National integration of European standards. Ann Oncol. 2007;18:969–970. - PubMed
    1. ESMO. Medical Oncology Status in Europe Survey (MOSES) http://www.esmo.org/policy/status-of-medical-oncology-in-europe.html.
    1. Hansen HH, Bajorin DF, Muss HB, et al. Recommendations for a global core curriculum in Medical Oncology. Ann Oncol. 2004;15:1603–1612. - PubMed
    1. EMEA. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/htms/human/epar/a.htm.
    1. Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 2008;26:313–325. - PubMed

Publication types

Substances